Literature DB >> 34662377

High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis.

P Martijn Kolijn1,2, Fatemeh Saberi Hosnijeh2, Florentin Späth3, Paul J Hengeveld1, Andreas Agathangelidis4,5, Manal Saleh2, Delphine Casabonne6,7, Yolanda Benavente6,7, Mats Jerkeman8,9, Antonio Agudo10, Aurelio Barricarte11,12, Caroline Besson13,14, Maria-Jose Sánchez15,6, María-Dolores Chirlaque12,16, Giovanna Masala17, Carlotta Sacerdote18, Sara Grioni19, Matthias B Schulze20,21, Alexandra Nieters22, Peter Engelfriet23, Magnus Hultdin24, James D McKay25, Roel C H Vermeulen2, Anton W Langerak1.   

Abstract

Chronic lymphocytic leukemia (CLL) is preceded by monoclonal B-cell lymphocytosis (MBL), a CLL precursor state with a prevalence of up to 12% in aged individuals; however, the duration of MBL and the mechanisms of its evolution to CLL remain largely unknown. In this study, we sequenced the B-cell receptor (BcR) immunoglobulin heavy chain (IGH) gene repertoire of 124 patients with CLL and 118 matched controls in blood samples taken up to 22 years prior to diagnosis. Significant skewing in the BcR IGH gene repertoire was detected in the majority of patients, even before the occurrence of lymphocytosis and irrespective of the clonotypic IGH variable gene somatic hypermutation status. Furthermore, we identified dominant clonotypes belonging to major stereotyped subsets associated with poor prognosis up to 16 years before diagnosis in 14 patients with CLL. In 22 patients with longitudinal samples, the skewing of the BcR IGH gene repertoire increased significantly over time to diagnosis or remained stable at high levels. For 14 of 16 patients with available samples at diagnosis, the CLL clonotype was already present in the prediagnostic samples. Overall, our data indicate that the preclinical phase of CLL could be longer than previously thought, even in adverse-prognostic cases.
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34662377     DOI: 10.1182/blood.2021012890

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  3 in total

1.  Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements.

Authors:  Davide Bagnara; Monica Colombo; Daniele Reverberi; Serena Matis; Rosanna Massara; Niccolò Cardente; Gianluca Ubezio; Vanessa Agostini; Luca Agnelli; Antonino Neri; Martina Cardillo; Stefano Vergani; Fabio Ghiotto; Andrea Nicola Mazzarello; Fortunato Morabito; Giovanna Cutrona; Manlio Ferrarini; Franco Fais
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

Review 2.  Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective.

Authors:  Marwan Kwok; Catherine J Wu
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

3.  T and NK Cells in IL2RG-Deficient Patient 50 Years After Hematopoietic Stem Cell Transplantation.

Authors:  Janine E Melsen; Monique M van Ostaijen-Ten Dam; Erik B van den Akker; Marij J P Welters; Kim C Heezen; Ingrid Pico-Knijnenburg; P Martijn Kolijn; Robbert G M Bredius; Remco van Doorn; Anton W Langerak; Marco W Schilham; Arjan C Lankester
Journal:  J Clin Immunol       Date:  2022-05-09       Impact factor: 8.542

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.